Pancreatic Cancer Research

ResearcherNational Cancer Center HospitalActive in the last 2 years

Satoshi Nara

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3516-8765; OpenAlex author ID A5009727563. Sources: OpenAlex.

Their work

Papers
24 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
91
Papers, trials and grants by year

2012: 3 papers · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: 2 papers · 2021: none · 2022: 4 papers · 2023: none · 2024: 5 papers · 2025: 2 papers · 2026: 3 papers

Papers 24

  1. MIF-CD74 axis facilitates MDSC infiltration in the tumor microenvironment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2026.218348↗
  2. Corrigendum to "MIF-CD74 axis facilitates MDSC infiltration in the tumor microenvironment of pancreatic ductal adenocarcinoma" [Cancer Lett. 645, (2026), 21834… Co-author DOI 10.1016/j.canlet.2026.218794↗
  3. Percutaneous abdominal lavage cytology screening reduces non-therapeutic laparotomy in patients with pancreatic cancer considered for curative-intent resection… Co-author DOI 10.1016/j.surg.2026.110444↗
  4. Neoadjuvant gemcitabine and S-1 in pancreatic ductal adenocarcinoma: Effects on nutritional status and pancreaticoduodenectomy outcomes. First author DOI 10.1016/j.surg.2024.109026↗
  5. Platform of single-molecule enzyme activity-based liquid biopsy for detection of pancreatic adenocarcinoma at early stages Co-author DOI 10.1101/2025.08.07.669035↗
  6. Oligo-like liver metastasis: A novel prognostic indicator to improve survival in pancreatic cancer. Co-author DOI 10.1002/ags3.12753↗
  7. Prevalence of HER3 Expression in Pancreatic Cancer Patients Treated With Systemic Chemotherapy. Co-author DOI 10.1002/cam4.70474↗
  8. Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemoth… Co-author DOI 10.1002/jhbp.12066↗
  9. Safety and feasibility of percutaneous abdominal lavage cytology screening (PACS) prior to surgical resection for pancreatic cancer. Co-author DOI 10.1007/s00261-024-04510-6↗
  10. Clinical development of a blood biomarker using apolipoprotein-A2 isoforms for early detection of pancreatic cancer. Co-author DOI 10.1007/s00535-023-02072-w↗
  11. Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5. Co-author DOI 10.1038/s41416-021-01639-9↗
  12. Prognostic Impact of Radiological Splenic Artery Involvement in Pancreatic Ductal Adenocarcinoma of the Body and Tail. Co-author DOI 10.1245/s10434-022-11950-1↗
  13. ASO Author Reflections: Prognostic Impact of Radiological Splenic Artery Involvement in Pancreatic Ductal Adenocarcinoma of the Body and Tail. Co-author DOI 10.1245/s10434-022-11957-8↗
  14. Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study. First author DOI 10.21873/anticanres.15547↗
  15. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients. Co-author DOI 10.1111/cas.14514↗
  16. O-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer. Co-author DOI 10.3390/cancers12092469↗
  17. Feasibility of resecting the portal vein only when necessary during pancreatoduodenectomy for pancreatic cancer. First author DOI 10.1002/bjs5.50130↗
  18. ASO Author Reflections: Clinical Significance of Further Subdivision of N Staging in Pancreatic Cancer. First author DOI 10.1245/s10434-019-07918-3↗
  19. Portal encasement: Significant CT findings to diagnose local recurrence after pancreaticoduodenectomy for pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.09.002↗
  20. Macroscopic features predict outcome in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00428-016-2026-6↗
  21. Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer. Co-author DOI 10.1038/srep18425↗
  22. Treatment outcome for systemic chemotherapy for recurrent pancreatic cancer after postoperative adjuvant chemotherapy. Co-author DOI 10.1016/j.pan.2012.07.016↗
  23. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Co-author DOI 10.1245/s10434-011-2020-9↗
  24. Total pancreatectomy with en bloc celiac axis resection for a pancreatic adenocarcinoma involving both the gastroduodenal artery and the celiac artery. Co-author DOI 10.5754/hge11687↗

Closest collaborators

The 25 strongest of 91 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Minoru Esaki · 16 shared papers, 2012–2026 · strength 2.43
  2. Nobuyoshi Hiraoka · 10 shared papers, 2016–2026 · strength 1.62
  3. Daisuke Ban · 6 shared papers, 2022–2026 · strength 1.32
  4. Kazuaki Shimada · 12 shared papers, 2012–2024 · strength 1.25
  5. Takeshi Takamoto · 5 shared papers, 2022–2025 · strength 1.02
  6. Shunsuke Sugawara · 4 shared papers, 2022–2026 · strength 0.78
  7. Chigusa Morizane · 6 shared papers, 2012–2025 · strength 0.70
  8. Ryosuke Umino · 2 shared papers, 2024–2026 · strength 0.48
  9. Yoji Kishi · 5 shared papers, 2012–2022 · strength 0.45
  10. Kazufumi Honda · 3 shared papers, 2020–2025 · strength 0.43
  11. Keisuke Sekine · 2 shared papers, 2026 · strength 0.40
  12. Kazunori Aoki · 2 shared papers, 2026 · strength 0.40
  13. Hiroyuki Tsunoda · 2 shared papers, 2026 · strength 0.40
  14. Hironori Fukuda · 2 shared papers, 2026 · strength 0.40
  15. Atsushi Ochiai · 2 shared papers, 2026 · strength 0.40
  16. Susumu Hijioka · 2 shared papers, 2024–2025 · strength 0.36
  17. Kei Kitamura · 2 shared papers, 2022 · strength 0.30
  18. Yoshinori Ino · 3 shared papers, 2016–2022 · strength 0.29
  19. Junji Furuse · 2 shared papers, 2022–2024 · strength 0.29
  20. Soichiro Morinaga · 2 shared papers, 2022–2024 · strength 0.29
  21. Takuji Okusaka · 3 shared papers, 2012–2024 · strength 0.27
  22. Ryo Saito · 1 shared paper, 2024 · strength 0.24
  23. Ayumi Kashiro · 2 shared papers, 2020–2024 · strength 0.23
  24. Shutaro Hori · 3 shared papers, 2016–2020 · strength 0.23
  25. Shingo X. Sakamoto · 1 shared paper, 2025 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.